Slide 1: CryoLife presentation, Steven G. Anderson, President & CEO
EXHIBIT 99.1 [PHOTO OF SCIENCE EQUIPMENT] [PHOTO OF BOY] [PHOTO OF SCIENCE EQUIPMENT] STEVEN G. ANDERSON, PRESIDENT & CEO [PHOTO OF SCIENCE EQUIPMENT] [PHOTO OF WOMAN AND CHILD] [PHOTO OF SURGEON]
Slide 2: Forward Looking Statements
Forward Looking Statements Statements made in this presentation that look forward in time or that express management's beliefs, expectations, hopes or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These future eve
Slide 3: CryoLife Investment Highlights
CryoLife Investment Highlights Focused Business Model • Products and technology addressing complex cardiac and vascular surgery Diversified Product Portfolio • Leading market share positions addressing $1B + total opportunity in various cardiovascular product segments Specialized Sales Force • ~70 p
Slide 4: Market Leading Product Platforms
Market Leading Product Platforms GRAPHIC SHOWING THE FOLLOWING: • Tissue Processing • Cardiac Allograft Tissue • Vascular Allograft Tissue • Medical Devices • Cardiogenesis • Investment in ValveXchange • Surgical Sealants & Hemostats • PerClot • BioGlue • BioFoam 4
Slide 5: Strategic Growth Objectives
Strategic Growth Objectives Drive Revenue Growth – Expand Gross Margins – Improve Profitability Acquisitive Growth • Acquire innovative products and technologies to accelerate top line • Focus on cardiac and vascular surgery • Target deals that have a clear path to shareholder value • Integrate prod
Slide 6: Recent Business Developments
Recent Business Developments • Starch Medical – September, 2010 – Worldwide distribution and manufacturing agreement for PerClot®, a novel second-generation hemostatic agent used in surgery • BioGlue Japan Launch – April, 2011 – Provided entry into second largest worldwide market for surgical hemost
Slide 7: Diversified and Growing Market Opportunities
Diversified and Growing Market Opportunities PIE CHARTS SHOWING THE FOLLOWING: Total Addressable Market $ in Millions 2011 BioGlue $464 CardioGenesis $175 BioFoam EU $30 PerClot EU $328 Allograft Cardiac Tissue $50 Allograft Vascular Tissue $68 2015 BioGlue $698 CardioGenesis $182 BioFoam EU $34 Per
Slide 8: Focused Sales and Distribution
Focused Sales and Distribution • ~70 (50 U.S.) person direct sales team poised to further penetrate cardiac and vascular surgeon market • Relationships with over 1,000 cardiac and vascular surgeons • Independent distributors covering 70+ countries • Leading annual cardiovascular surgeon training eve
Slide 9: BioGlue & BioFoam Protein Hydrogel Technologies
BioGlue® & BioFoam® Protein Hydrogel Technologies BioGlue • Dominant adhesive/sealant for cardiovascular surgery; over 650,000 procedures worldwide • Overcomes air and fluid leakage challenges with sutures and staples • 4-5x tensile strength of fibrin sealants • U.S., European and Shonin (Japanese)
Slide 10: PerClot - Significant Growth Opportunity
PerClot® - Significant Growth Opportunity • Next generation hemostatic agent derived from plant starch; rapid blood absorption • $1.3 Billion worldwide market growing to ~$1.9 billion in 2015 • Decreases disease transmission and immunologic response; no human or animal components • Ready-to-use at s
Slide 11: Cardiac Allograft Tissue
Cardiac Allograft Tissue • Dominant player with >50% market share • Ideal for young women and children • Lower rate of calcification vs. animal tissues • No need for blood thinners vs. mechanical valves • No synthetic materials vs. porcine/bovine valves • Broad product offering for cardiac reconstru
Slide 12: Vascular Allograft Tissue
Vascular Allograft Tissue • Vascular disease is a significant co-morbidity of diabetes • Broad product offering – Saphenous veins, femoral veins & arteries, aortoiliac grafts – Used in limb salvage due to vascular disease, aortoiliac replacements, dialysis access, cardiac bypass • Overcomes poor per
Slide 13: Transmyocardial Revascularization (TMR)
Transmyocardial Revascularization (TMR) • Treatment for no-option patients with severe angina, incomplete revascularization and chronic ischemic heart disease • Proprietary intramyocardial catheters • Intraoperative procedure performed by cardiac surgeon • Epicardial nature of procedure allows for d
Slide 14: Cardiogenesis Acquisition
Cardiogenesis Acquisition Increases Addressable Market Opportunity • Adds $175 million initially, and up to $700 million with biologics Expanded Portfolio Allows For Significant Growth • 2010 revenue of $11.3M with >80% gross margin Strong Anticipated ROI • Expected break even within first year (exc
Slide 15: Next Generation Phoenix Intramyocardial Delivery System
Next Generation Phoenix Intramyocardial Delivery System • Innovative Revascularization approach utilizing autogenous stem cell biologics to increase angiogenesis • CE Mark Approval; Planning 30 patient European study to commence in 2012 • U.S. clinical trials expected to commence in 2012 Phoenix Pro
Slide 16: ValveXchange: Investing in Complementary Heart Valve Technology
ValveXchange: Investing in Complementary Heart Valve Technology Vanguard™ Transapical [PHOTO OF MEDICAL TECHNOLOGY] • Next-generation lifetime heart valve replacement technology – Features potential transapical leaflet replacement; potentially overcomes long-term leaflet wear, which currently requir
Slide 17: Leveraging Core Business to Invest in Growth Opportunities
Leveraging Core Business to Invest in Growth Opportunities TIMELINE GRAPHIC SHOWING THE FOLLOWING: BioFoam CE Mark 2010 Perclot WW distribution and manufacturing agreement with Starch Medical BioGlue Japan Approval Perclot EU Launch 2011 BioGlue Japan Launch Cardiogenesis Acquisition ValveXchange Eq
Slide 18: Growing Annual Revenues
Growing Annual Revenues ($ in millions) BAR CHART SHOWING THE FOLLOWING: 2006 $81.3 2007 $94.8 2008 $105.0 2009 $111.7 2010 $116.6 2011E $121.0 2012E $130.0 2013E $140.0 18
Slide 19: Strong Cash & Cash Equivalents
Strong Cash & Cash Equivalents ($ in millions) BAR CHART SHOWING THE FOLLOWING: 2007 $17.5 2008 $22.8 2009 $35.1 2010 $40.8 9/30/2011 $26.0* Investments over past 2 years (prior to 9/30/2011) PerClot Technology Acquisition $6.75 million Cardiogenesis Acquisition $21.7 million Investment in ValveXcha
Slide 20: Expanding Pipeline Drives Market Opportunity
Expanding Pipeline Drives Market Opportunity Total Addressable Worldwide Market PIE CHARTS SHOWING THE FOLLOWING: 2011: $1.1B Current Products $1.1B 2015: $3.5B Current Products $1.5B PerClot Worldwide $1.4B BioFoam US $77 CardioGenesis (Phoenix) $518 Current Products : BioGlue, Cardiogenesis, Biofo
Slide 21: CryoLife.com
4, CryoLife Life Restoring Technologies ™ CryoLife.com 21
Slide 22: Forward Looking Statement
FORWARD LOOKING STATEMENT Statements made in this presentation that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the
Slide 23: Forward Looking Statement - continued
FORWARD LOOKING STATEMENT - continued Any business development efforts and/or R&D investments are subject to delays, cost overages and regulatory difficulties, and efforts to fully integrate future acquisitions and new product offerings into our business, or efforts relating to R&D and clinical tria
Slide 24: Forward Looking Statement - continued
FORWARD LOOKING STATEMENT - continued Medafor has filed counter-claims against us with respect to our lawsuit against Medafor, and if Medafor is successful in its claims, our revenues and profitability may be materially, adversely impacted, we may be unsuccessful in our efforts to market and sell Pe
Slide 25: Slide 25